消化性溃疡药物市场规模、份额、成长分析，按药物类型、溃疡类型、最终用户、地区 - 产业预测，2025-2032

2023年消化性溃疡药物市场规模将为47.6亿美元，预测期内（2025-2032年）复合年增长率为3.50%，从2024年的49.3亿美元增长到2032年的64.9亿美元。

在多种驱动因素​​的推动下，全球消化性溃疡治疗市场呈现上升趋势。消化性溃疡病影响着全球数百万人，这种胃肠道疾病的盛行率不断上升、人口老化以及吸烟和饮酒等不健康生活方式的迅速增加正在推动这一市场。医疗技术的进步和创新配方的推出进一步推动了市场的成长。然而，挑战也存在，例如学名药的可用性和替代治疗方法的兴起。然而，人们对早期诊断和有效治疗重要性的认识不断提高，预计将确保持续成长并推动市场在面对这些挑战时向前发展。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 抑制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析

按药物类型分類的消化性溃疡治疗药物市场规模

• 市场概况
• 质子帮浦抑制剂
• H2拮抗剂
• 抗生素
• 其他的

消化性溃疡治疗药物市场规模：依溃疡类型

• 市场概况
• 胃溃疡
• 十二指肠溃疡
• 食道溃疡

消化性溃疡治疗药物市场规模：依最终用户划分

• 市场概况
• 医院
• 零售药房
• 网路药房

消化性溃疡治疗药物市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2022-2024）

主要企业简介

• AstraZeneca plc.（United Kingdom）
• Pfizer Inc.（United States）
• Novartis AG（Switzerland）
• Takeda Pharmaceutical Company Limited（Japan）
• GlaxoSmithKline plc.（United Kingdom）
• Sanofi SA（France）
• Johnson & Johnson（United States）
• Merck & Co., Inc.（United States）
• Bayer AG（Germany）
• AbbVie Inc.（United States）
• Eli Lilly and Company（United States）
• Daiichi Sankyo Company, Limited（Japan）
• Bristol-Myers Squibb Company（United States）
• Mylan NV（Netherlands）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Sun Pharmaceutical Industries Ltd.（India）
• Dr. Reddy's Laboratories Ltd.（India）
• Cipla Ltd.（India）
• Lupin Ltd.（India）
• Zydus Cadila（India）

结论和建议

Peptic Ulcer Drugs Market size was valued at USD 4.76 Billion in 2023 and is poised to grow from USD 4.93 Billion in 2024 to USD 6.49 Billion by 2032, growing at a CAGR of 3.50% during the forecast period (2025-2032).

The global peptic ulcer drugs market is on an upward trajectory, fueled by various driving factors. With millions affected by peptic ulcer disease globally, the market is bolstered by the increasing prevalence of this gastrointestinal disorder, an expanding aging population, and a surge in unhealthy lifestyle choices like smoking and alcohol use. Technological advancements in medicine and the introduction of innovative drug formulations further enhance market growth. However, challenges exist, including the availability of generic drugs and the rise of alternative treatment options. Nonetheless, heightened awareness around the significance of early diagnosis and effective treatment is anticipated to propel the market forward, ensuring continued growth in the face of these challenges.

Top-down and bottom-up approaches were used to estimate and validate the size of the Peptic Ulcer Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Peptic Ulcer Drugs Market Segmental Analysis

Global Peptic Ulcer Drugs Market is segmented by drug type, ulcer type, end user and region. Based on drug type, the market is segmented into proton pump inhibitors, H2 antagonists, antibiotics and others. Based on ulcer type, the market is segmented into gastric ulcer, duodenal ulcer and esophageal ulcer. Based on end user, the market is segmented into hospitals, retail pharmacies and online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Peptic Ulcer Drugs Market

The global peptic ulcer drugs market is significantly driven by the rising prevalence of peptic ulcers across the globe. This common gastrointestinal condition impacts millions, creating a heightened demand for effective treatment alternatives. Contributing factors such as unhealthy lifestyles, increased stress levels, and the regular use of non-steroidal anti-inflammatory drugs (NSAIDs) are fueling the surge in peptic ulcer cases. As a result, there is a continued push for innovative and effective medications, fostering overall growth in the market. This increasing incidence emphasizes the urgent need for solutions, making the peptic ulcer drugs market an area of considerable focus and expansion.

Restraints in the Peptic Ulcer Drugs Market

The global peptic ulcer drugs market faces restraint due to the presence of various alternative treatment options. Beyond conventional pharmaceutical interventions, patients often have access to non-pharmacological methods, such as lifestyle alterations, dietary adjustments, and natural remedies, which are perceived as effective alternatives for managing peptic ulcers. This preference for non-drug approaches can significantly diminish the demand for traditional medications. Additionally, concerns regarding the potential side effects and long-term risks associated with the use of peptic ulcer drugs may further deter patients and healthcare providers, thereby affecting overall market dynamics and growth potential.

Market Trends of the Peptic Ulcer Drugs Market

A prominent market trend in the global peptic ulcer drugs sector is the rising preference for proton pump inhibitors (PPIs) as the primary treatment choice. This shift is fueled by the efficacy and safety of PPIs, which outperform other medication classes in reducing stomach acid production and providing lasting relief from ulcer symptoms. Enhanced drug formulations have further increased the bioavailability and compliance of PPIs in patients, making them more appealing. Such factors are contributing to a robust demand for these medications, positioning PPIs as a cornerstone in peptic ulcer therapies and fostering growth within the overall market landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Peptic Ulcer Drugs Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Proton Pump Inhibitors
• H2 Antagonists
• Antibiotics
• Others

Global Peptic Ulcer Drugs Market Size by Ulcer Type & CAGR (2025-2032)

• Market Overview
• Gastric Ulcer
• Duodenal Ulcer
• Esophageal Ulcer

Global Peptic Ulcer Drugs Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Retail Pharmacies
• Online Pharmacies

Global Peptic Ulcer Drugs Market Size & CAGR (2025-2032)

• North America (Drug Type, Ulcer Type, End User)
  • US
  • Canada
• Europe (Drug Type, Ulcer Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Ulcer Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Ulcer Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Ulcer Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AstraZeneca plc. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations